Description
Larotrectinib, sold under the brand name Vitrakvi, is a medication for the treatment of cancer. It is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC. It was discovered by Array BioPharma and licensed to Loxo Oncology in 2013.
Larotrectinib was initially awarded orphan drug status in 2015, for soft tissue sarcoma, and breakthrough therapy designation in 2016 for the treatment of metastatic solid tumors with NTRK fusion. Some clinical trial results were announced in 2017. On 26 November 2018, Larotrectinib was approved by the FDA.
Larotrectinib was approved for medical use in the European Union in September 2019. It was approved for medical use in Australia in August 2020.
HOW AND WHERE TO BUY larotrectinib oral solution?
You can order larotrectinib oral solution through Medvitaz Pharma Solutions under Named Patient Program (NPP). Medvitaz provides patients and physicians access to commercially approved medicines that are not available to them in their own country. Medvitaz objectives is to make quality medicines available at affordable prices for patients and physicians. To get best retail price/cost of larotrectinib oral solution in India, Call 8750295029 or Email [email protected]. FDA approved drugs of Australia, Canada, Delhi, EU, India, New Zealand, Singapore, Switzerland, Turkey & USA.